Evaluating programmed death‐ligand 1 (PD‐L1) in head and neck squamous cell carcinoma: concordance between the 22C3 PharmDx assay and the SP263 assay on whole sections from a multicentre study

AIMS: The introduction of immunotherapy for patients with head and neck squamous cell carcinoma (HNSCC) raises the need for harmonisation between different types of antibody and immunohistochemistry platform for evaluating the expression of PD‐L1 by use of the combined positive score (CPS) in this t...

Descripción completa

Detalles Bibliográficos
Autores principales: Cerbelli, Bruna, Girolami, Ilaria, Eccher, Albino, Costarelli, Leopoldo, Taccogna, Silvia, Scialpi, Renzo, Benevolo, Maria, Lucante, Teresa, Luigi Alò, Piero, Stella, Francesca, Gemma Pignataro, Maria, Fadda, Guido, Perrone, Giuseppe, D’Amati, Giulia, Martini, Maurizio
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299113/
https://www.ncbi.nlm.nih.gov/pubmed/34496080
http://dx.doi.org/10.1111/his.14562

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9299113/
https://www.ncbi.nlm.nih.gov/pubmed/34496080
http://dx.doi.org/10.1111/his.14562

Ejemplares similares